{"id":499787,"date":"2020-08-01T00:00:00","date_gmt":"2020-07-30T18:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=499787"},"modified":"2020-07-30T18:34:01","modified_gmt":"2020-07-30T18:34:01","slug":"autosomal-dominant-polycystic-kidney-disease-adpkd-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/autosomal-dominant-polycystic-kidney-disease-adpkd-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_499787.html","title":{"rendered":"Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast"},"content":{"rendered":"
\"Autosomal<\/a><\/p>\n
\n
Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease (ADPKD), historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease (ADPKD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic disorder which causes pathological cystic changes to the kidney and is characterized by numerous renal and systemic manifestations. Renal manifestations are produced by the progressive and continuous enlargement and proliferation of fluid-filled cysts, leading to enlargement of the kidney up to five times the normal volume in the years prior to the development of kidney failure. <\/p>\n

ADPKD may lead to development of end-stage renal disease (ESRD) and is the fourth most common renal disease requiring renal replacement therapy (RRP). The most common extrarenal manifestation is olycystic liver disease (PLD), which is more common in women than in men.  Genetic mutation plays a major role in the pathogenesis of ADPKD, mainly mutations in the PKD1, PKD2 genes leads to cyst formation and its progressive growth. <\/p>\n

 <\/p>\n

Get FREE sample copy at: <\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/autosomal-dominant-polycystic-kidney-disease-market<\/a><\/strong><\/p>\n

 \"autosomal-dominant-polycystic-kidney-disease-ADPKD-market\"<\/p>\n

The Autosomal Dominant Polycystic Kidney Disease (ADPKD) market report<\/strong> also covers emerging drugs, current treatment practices, Autosomal Dominant Polycystic Kidney Disease (ADPKD) market share of the individual therapies, current and forecasted Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment practice\/algorithm<\/strong>, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. <\/p>\n

 <\/p>\n

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Key Facts<\/strong><\/p>\n

ADPKD affects nearly 12.4 million people worldwide. About nine out of every 10 people with PKD have the autosomal dominant form.<\/p>\n

The prevalence of ADPKD is estimated to range from 1 in 400 to 1000 live births, with 5,000–6,000 new cases diagnosed each year (Rashid, 2018).<\/p>\n

About 1 in 2 people with ADPKD develop kidney failure by the age of 60 and will need dialysis or a kidney transplant.<\/p>\n

The United States has the highest percentage of diagnosed & treated patients of ADPKD in the 7MM.<\/p>\n

 <\/p>\n

Key Benefits of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Report<\/strong><\/p>\n